PharmAthene (NYSE:PIP) Getting Somewhat Favorable Press Coverage, Study Finds
Media stories about PharmAthene (NYSE:PIP) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. PharmAthene earned a daily sentiment score of 0.23 on Accern’s scale. Accern also assigned media coverage about the financial services provider an impact score of 45.6826719847516 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Shares of PharmAthene (PIP) opened at 0.65 on Thursday. The firm’s 50-day moving average price is $0.77 and its 200-day moving average price is $2.08. PharmAthene has a 52-week low of $0.47 and a 52-week high of $3.50.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/08/10/pharmathene-nysepip-getting-somewhat-favorable-press-coverage-study-finds.html.
Pharmathene, Inc (Pharmathene) is a biodefense company. The Company is focused on the development of medical counter measures against biological and chemical threats. The Company is involved in the development of two next generation anthrax vaccines. The Company’s anthrax vaccines use recombinant protective antigen (rPA) manufacturing processes.
Receive News & Ratings for PharmAthene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmAthene Inc. and related companies with MarketBeat.com's FREE daily email newsletter.